Settlement Reached in Benicar Multidistrict Litigation

Posted on 08/08/2017Back

Daiichi Sankyo, Inc., a Japanese pharmaceutical company, agreed to pay up to $300 million to settle approximately 2,500 cases pending against its blood pressure medications, Benicar, Benicar HCT, Azor, and Tribenzor.

The settlement was reached as a part of a multidistrict litigation, In re: Benicar (Olmesartan) Products Liability Litigation, MDL No. 2606, and was announced on August 1, 2017. A press release summarizing the settlement indicated:

“These drugs have been linked to severe and sometimes life-threatening gastrointestinal injuries including sprue-like enteropathy, celiac disease-like symptoms and gastrointestinal conditions that inhibit a person’s ability to absorb nutrients, due to changes in the intestinal tract. The litigation was resolved as the parties prepared for pre-trial hearings, and an anticipated first trial in federal court”.

Benicar, a high-blood pressure medication, has been linked to dangerous side effects. Patients taking Benicar could develop sprue-like enteropathy, a condition which attacks the body’s healthy intestinal villi. Intestinal villi line the small intestine and play a major role in nutrition absorption. Sprue-like enteropathy limits the body’s ability to absorb nutrients and sends food and drink through the system much faster than is normal or healthy. Failure of intestinal villi can lead to:

  • Severe, chronic diarrhea
  • Rapid, unhealthy weight loss
  • Abdominal pain
  • Dehydration and
  • Malabsorption

If left untreated, sprue-line enteropathy can cause serious injury or death.

There is a deadline of August 23, 2017 to register a claim. A signed retainer is necessary before that date. Please contact GoldenbergLaw immediately by dialing (612) 333-4662 if you have questions about a potential case.

Category News